These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15180859)

  • 21. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination.
    Arcaini L; Burcheri S; Rossi A; Passamonti F; Paulli M; Boveri E; Brusamolino E; Orlandi E; Molteni A; Pulsoni A; Cox MC; Orsucci L; Fabbri A; Frezzato M; Voso MT; Zaja F; Montanari F; Pascutto C; Morra E; Cortelazzo S; Lazzarino M
    Oncologist; 2006 Mar; 11(3):285-91. PubMed ID: 16549813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topoisomerase IIalpha expression as an independent prognostic factor in Hodgkin's lymphoma.
    Doussis-Anagnostopoulou IA; Vassilakopoulos TP; Thymara I; Korkolopoulou P; Angelopoulou MK; Siakantaris MP; Kokoris SI; Dimitriadou EM; Kalpadakis C; Matzouranis M; Kaklamanis L; Panayiotidis P; Kyrtsonis MC; Androulaki A; Patsouris E; Kittas C; Pangalis GA
    Clin Cancer Res; 2008 Mar; 14(6):1759-66. PubMed ID: 18347177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma.
    Donskov F; von der Maase H
    J Clin Oncol; 2006 May; 24(13):1997-2005. PubMed ID: 16648500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
    Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
    Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
    Aldrighetti L; Castoldi R; Di Palo S; Arru M; Stella M; Orsenigo E; Gavazzi F; Ferla G; Di Carlo V; Staudacher C
    Chir Ital; 2005; 57(5):555-70. PubMed ID: 16241086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials.
    Mandrekar SJ; Schild SE; Hillman SL; Allen KL; Marks RS; Mailliard JA; Krook JE; Maksymiuk AW; Chansky K; Kelly K; Adjei AA; Jett JR
    Cancer; 2006 Aug; 107(4):781-92. PubMed ID: 16847887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients.
    Beal K; Allen L; Yahalom J
    Cancer; 2006 Jun; 106(12):2652-6. PubMed ID: 16700039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case of relapsed CD20(+) mixed-cellularity Hodgkin disease treated with sequential rituximab and radiotherapy.
    Karamouzis MV; Apostolikas N; Georganta C; Lainakis G; Kandylis K; Rigatos G
    Am J Hematol; 2004 Dec; 77(4):418-9. PubMed ID: 15551291
    [No Abstract]   [Full Text] [Related]  

  • 32. Advances in biology, diagnostics, and treatment of Hodgkin's disease.
    Küppers R; Yahalom J; Josting A
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):66-76. PubMed ID: 16399588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
    Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
    Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
    Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
    J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
    Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
    Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [CD20 antigen of Hodgkin and Reed-Sternberg cells as possible prognostic factor in patients with Hodgkin's lymphoma--preliminary reports].
    Rygoł B; Krzemień S; Pajak J; Konicki P; Kowal E; Spychałowicz W; Mykała-Cieśla J; Gasińska T; Krajewski-Siuda K
    Pol Arch Med Wewn; 2006 Sep; 116(3):838-44. PubMed ID: 18652276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.